Understanding a little about the prostate gland and its biology is not only interesting, but it allows us to ask some important questions that can positively inform our treatment decisions and eventually the outcomes. On the other hand, it also can add to the confusion we all face in making the best clinical decisions. Like [...]
Clinical trials have shown that there is an overall survival and radiographic progression-free survival benefit derived from abiraterone acetate (Zytiga) in the treatment of men with metastatic castration resistant prostate cancer (mCRPC). A new retrospective study published online, ahead of print, shows this trend is true regardless of a man's Gleason score at diagnosis, despite [...]
Many people consider food diet important in both prostate cancer prevention and in controlling its progression. Dietary derived agents, such as the flavonoids derived from fruits and vegetables should be of particular interest for prostate cancer survivors, as they seem to offer both chemo-prevention and an antioxidant effect along with a favorable safety and side-effect [...]
The Response Evaluation Criteria In Solid Tumors (RECIST) was first published in 2000 and then updated in 2009. RECIST is a set of published rules that attempt to define when cancer tumors, including prostate cancer tumors, improve ("respond"), stay the same ("stabilize"), or worsen ("progress") during treatment. This criteria has become very important as the majority [...]
Understanding a little about the prostate gland and its biology is not only interesting, but it allows us to ask some important questions that can be very specific to our prostate cancer treatment decisions and our eventual outcomes from these decisions. It also can simply add to the confusion we all face in making the [...]